- Trials with a EudraCT protocol (186)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
186 result(s) found for: Implant failure.
Displaying page 7 of 10.
EudraCT Number: 2010-023241-29 | Sponsor Protocol Number: 747-204 | Start Date*: 2011-02-10 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals Inc | |||||||||||||
Full Title: A Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Obeticholic Acid (INT-747) for the Treatment of Portal Hypertension (PESTO) | |||||||||||||
Medical condition: Portal Hypertension in Patients with Cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005243-97 | Sponsor Protocol Number: D6160C00047 | Start Date*: 2005-11-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar Therapy in Patients with Type 2 Diabetes Mel... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002498-36 | Sponsor Protocol Number: CCN017 | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | |||||||||||||
Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception | |||||||||||||
Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003952-29 | Sponsor Protocol Number: BAY63-2521/15681 | Start Date*: 2015-08-25 |
Sponsor Name:Bayer AG | ||
Full Title: Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (... | ||
Medical condition: Hypertension, Pulmonary | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) IT (Trial now transitioned) GB (Completed) DE (Trial now transitioned) ES (Prematurely Ended) PL (Completed) Outside EU/EEA BE (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002207-26 | Sponsor Protocol Number: TP-434-021 | Start Date*: 2016-12-15 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections | |||||||||||||
Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) AT (Completed) SK (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007323-64 | Sponsor Protocol Number: P441201CD | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:Serentis Limited | |||||||||||||
Full Title: A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000551-81 | Sponsor Protocol Number: HZA116492 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™... | |||||||||||||
Medical condition: Subject with persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001409-15 | Sponsor Protocol Number: 201012 | Start Date*: 2016-01-07 | |||||||||||
Sponsor Name:GlaxoSmithKlineResearch & Developemnt Ltd | |||||||||||||
Full Title: Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD. | |||||||||||||
Medical condition: Subjects with COPD. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000522-58 | Sponsor Protocol Number: NPM001 | Start Date*: 2014-10-02 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or ad... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002669-37 | Sponsor Protocol Number: GB002-2101 | Start Date*: 2020-10-08 | |||||||||||
Sponsor Name:GB002, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arter... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003673-10 | Sponsor Protocol Number: AV003 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Bond Avillion 2 Development LP | ||||||||||||||||||
Full Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in S... | ||||||||||||||||||
Medical condition: Moderate to severe asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SK (Completed) ES (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004534-38 | Sponsor Protocol Number: C928-011 | Start Date*: 2021-10-11 | |||||||||||
Sponsor Name:DURECT Corporation | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis | |||||||||||||
Medical condition: Alcoholic hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000585-36 | Sponsor Protocol Number: 204990 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
Medical condition: Subjects with COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023900-29 | Sponsor Protocol Number: MAF-AGN-OPH-RET-004 | Start Date*: 2011-08-23 | ||||||||||||||||
Sponsor Name:Allergan Pharmaceuticals Ireland | ||||||||||||||||||
Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion | ||||||||||||||||||
Medical condition: Macula oedema secondary to branch retinal vein occlusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004168-30 | Sponsor Protocol Number: STS001 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma | |||||||||||||
Medical condition: Metastatic or advanced soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003788-82 | Sponsor Protocol Number: SA2115 | Start Date*: 2022-02-15 | ||||||||||||||||
Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital | ||||||||||||||||||
Full Title: An open label phase 2 study on propranolol and pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma – a Scandinavian Sarcoma Group collaboration | ||||||||||||||||||
Medical condition: Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) NO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000168-28 | Sponsor Protocol Number: IBCSG25-02/BIG3-02 | Start Date*: 2005-11-21 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer | |||||||||||||
Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002455-29 | Sponsor Protocol Number: 15-AVP-786-303 | Start Date*: 2018-07-31 | |||||||||||
Sponsor Name:Avanir Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation... | |||||||||||||
Medical condition: Agitation Associated with Dementia of the Alzheimer's Type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) FR (Completed) PL (Completed) BG (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004732-19 | Sponsor Protocol Number: 6043-PG-PSC-206 | Start Date*: 2015-07-20 | |||||||||||||||||||||
Sponsor Name:LETI Pharma GmbH | |||||||||||||||||||||||
Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum versus Placebo in Patients with Allergic Rhinitis and/or R... | |||||||||||||||||||||||
Medical condition: Allergic Rhinitis and / or Rhinoconjunctivitis with or without Intermittent Asthma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002981-64 | Sponsor Protocol Number: CC-10004-UC-001 | Start Date*: 2015-08-13 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS | |||||||||||||
Medical condition: Subjects with active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
